OLANZAPINE        SUPPORTING DATA 
Reduced relapse rate
Longer time to relapse
At least as effective as lithium
OFC in bipolar depression
No treatment-emergent mania
Improvements in HR-Qol
Supporting data
Fewer drop-outs than lithium
No QTc prolongation
Usage
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 OFC: quality of life in bipolar depression
Author: Shi, et al.
Title: Effects of olanzapine alone and olanzapine/fluoxetine combination on health related quality of life in patients with bipolar depression: secondary analysis of a double blind, placebo-controlled randomized trial.
Reference: Clin Ther 2004;26:125-34.
Purpose: Secondary analysis to investigate the effect of OFC on HR-QoL.
Study design: Randomized, double-blinded trial (secondary analysis).
Follow up: 8 weeks.
Patients: 833 (86 OFC, 370 olanzapine, and 377 placebo).
Treatment: OFC (6 and 25 mg/day, 12 and 25 mg/day, or 12 and 50 mg/day), olanzapine (5–20 mg/day), or placebo.
Results: Long-term treatment with olanzapine or OFC improved HR-QoL in bipolar depressed patients compared with placebo. OFC improved HR-QoL to a greater extent than olanzapine alone.
health-related quality of life
health-related quality of life
health-related quality of life
olanzapine fluoxetine combination
olanzapine fluoxetine combination
olanzapine fluoxetine combination
olanzapine fluoxetine combination
olanzapine fluoxetine combination
quality of life
quality of life
quality of life


 
  
home help sitemap acronyms help sitemap home